Glenmark Pharmaceuticals delivered a robust performance in Q4 and FY26, reporting double-digit growth across revenue and profitability, alongside major strategic wins in global partnerships and product expansion.
The company posted consolidated revenue of Rs. 37,706 million in Q4 FY26, up 15.8% year-on-year, while full-year FY26 revenue surged 27.5% to Rs. 169,825 million.
EBITDA for the March quarter stood at Rs. 7,626 million, with margins at 20.2%, while Profit After Tax (PAT) came in at Rs. 3,013 million, reflecting a PAT margin of 7.6%. For FY26, EBITDA reached Rs. 45,724 million with margins of 26.9%, and PAT stood at Rs. 13,620 million, with margins of 7.8%.
A major highlight of the year was a landmark licensing deal with AbbVie through IGI for ISB 2001, built on the BEAT protein platform for oncology and autoimmune diseases. The deal includes a USD 700 million upfront payment, a potential total value of USD 1.925 billion, and tiered double-digit royalties on net sales, with Glenmark set to lead commercialization in emerging markets.
Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharma, said, “FY26 has been a defining year in Glenmark’s evolution. We delivered strong business performance while making meaningful progress against the strategic priorities that will shape our future.
"The landmark AbbVie partnership validated the strength of our innovation capabilities and the global relevance of our science. During the year, we expanded our portfolio of differentiated products including the successful launches of key generic respiratory products in the US which demonstrates continued expertise in our core therapeutic areas."
He added: "We also accelerated the global momentum of RYALTRIS and our collaborations during FY26 reinforced our position as the partner of choice for innovative molecule launches across markets.
"We are building an organization that combines the scale and resilience of a global pharmaceutical business with the scientific ambition of an innovation-driven organization amidst the evolving global landscape. As we look ahead, we remain focused on disciplined execution, differentiated science, and creating greater impact for patients around the world.”
Operationally, Glenmark strengthened its US respiratory portfolio with the first generic approval of Flovent HFA 44 mcg (CGT designation) and approval of Fluticasone Propionate Nasal Spray OTC, along with filings for three additional ANDAs.
Its key drug RYALTRIS recorded over 50% growth in secondary sales across commercial markets and expanded into the US with full-scale commercialization, while also gaining approvals and launches in China and Thailand.
The company also expanded its oncology footprint in India and emerging markets through in-licensing deals for Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma, further strengthening its cancer therapy pipeline.
In India, Glenmark’s performance outpaced the industry, growing secondary sales at 1.5x IPM growth and ranking as the second-fastest-growing company among the top 15 pharma players, according to IQVIA. Key launches in oncology, respiratory, and diabetes segments also supported domestic momentum.
Internationally, Glenmark expanded its dermatology presence in Europe with the approval and UK launch of WINLEVI, reinforcing its push into differentiated specialty therapies.
Overall, FY26 marked a year of strong financial delivery paired with aggressive portfolio expansion and high-value global partnerships, positioning Glenmark for its next phase of growth in innovation-led pharmaceuticals.
